Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.91 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyruvate SCHEMBL148220 | 0.95 | — | — | |
| Pyruvate SCHEMBL18226 | 0.91 | — | — | |
| Pyruvate SCHEMBL6743473 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL598199 | 0.91 | — | — | |
| Pyruvate SCHEMBL1332958 | 0.91 | — | — | |
| Pyruvate SCHEMBL7936306 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL1332703 | 0.91 | — | — | |
| Pyruvate SCHEMBL597153 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL3745552 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL597752 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220170056-A1 | COMPOSITIONS AND METHODS FOR BIOSYNTHESIS OF TERPENOIDS OR CANNABINOIDS IN A HETEROLOGOUS SYSTEM | INMED PHARMACEUTICALS INC. (CA) | 2022-06-02 | — | — | US | disclosed |
| EP-3935178-A1 | COMPOSITIONS AND METHODS FOR BIOSYNTHESIS OF TERPENOIDS OR CANNABINOIDS IN A HETEROLOGOUS SYSTEM | Inmed Pharmaceuticals Inc. (CA) | 2022-01-12 | — | — | EP | disclosed |
| EP-2861715-B1 | CATALASE IN GROWTH MEDIA | EUCODIS BIOSCIENCE GMBH (AT) | 2018-09-19 | — | — | EP | disclosed |
| US-9951306-B2 | Catalase in growth media | EUCODIS BIOSCIENCE GMBH (AT) | 2018-04-24 | — | — | US | disclosed |
| US-20150152466-A1 | CATALASE IN GROWTH MEDIA | BIOSYNTH GMBH (AT) | 2015-06-04 | — | — | US | disclosed |
| EP-2861715-A1 | CATALASE IN GROWTH MEDIA | Eucodis Bioscience GmbH (AT) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013186253-A1 | CATALASE IN GROWTH MEDIA | EUCODIS BIOSCIENCE GMBH (AT) | 2013-12-19 | — | — | WO | disclosed |
| US-20040132813-A1 | Glycerol-lactate esters for use as an energy supplement during exercise and recovery | BROOKS GEORGE A (US) | 2004-07-08 | — | — | US | disclosed |
| US-6743821-B2 | CONTROLLING BLOOD GLUCOSE CONCENTRATION | BROOKS GEORGE A (US) | 2004-06-01 | — | — | US | disclosed |
| US-20030013763-A1 | Glycerol-lactate esters for use as an energy supplement during exercise and recovery | BROOKS GEORGE A (US) | 2003-01-16 | — | — | US | disclosed |
| US-6482853-B1 | Lactate thiolester for cardiac energy resuscitation and prevention of reperfusion injury and use as an energy supplement during exercise and recovery | BROOKS GEORGE A (US) | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013763-A1 | Glycerol-lactate esters for use as an energy supplement during exercise and recovery | GYS1, PYGM, GYS2 | CA4 1398/4885CA1 2201/4885TSHR 2671/4885 |
| US-20040132813-A1 | Glycerol-lactate esters for use as an energy supplement during exercise and recovery | GYS1, PYGM, GYS2 | CA4 1398/4885CA1 2201/4885TSHR 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.